Search

everythinglearnresearchcommunity

for

Search:↓

No link between scalp patterns and alopecia severity in children, but more severe cases often had nail abnormalities.

Plant-based chemicals may help hair growth and prevent hair loss but need more research to compete with current treatments.

Combining OMP with cyclosporine can effectively treat severe alopecia areata in children.

Alopecia areata is a reversible, autoimmune-related hair loss that can have significant emotional impact and uncertain treatment effectiveness.

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

The research suggests that autophagy-related genes might play a role in causing alopecia areata.

The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.

TGPC plus CGT is effective and safe for treating severe alopecia areata in children.

Platelet-Rich Plasma (PRP) could potentially help regrow hair in people with Alopecia Areata, but more research is needed to confirm its effectiveness.

Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.

Alopecia areata causes varying hair loss and nail changes, and treatments include topical, systemic, and injectable therapies.

Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.

New treatments for severe alopecia areata show promise but lack standard approval.

The paper concludes that recognizing bitemporal alopecia areata is important for early treatment and preventing its progression.

Microneedling with PRP is a safe and effective way to treat chronic alopecia areata, improving hair regrowth with minimal side effects.

Alopecia areata patients may have higher blood pressure and blood sugar, indicating a future risk of metabolic issues.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Oxidative stress is linked to mild patchy alopecia areata.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

No cure exists for alopecia areata, and treatments are personalized.

Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.

A synthetic drug and a South American herb may help treat alopecia areata in Chinese men.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.